-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The US Food and Drug Administration revised the emergency use authorization for the Moderna and Pfizer new crown vaccines on the 12th, approving the upgraded versions of these two vaccines for younger age groups as booster shots to provide better protection
against the Omicron variant.
against the Omicron variant.
Under the latest authorization, the FDA has expanded the age range for the upgraded Moderna and Pfizer vaccines, allowing the upgraded Moderna vaccine to be applied to people 6 years of age and older, and the upgraded Pfizer vaccine to people
5 years of age and older.
Members of the public can receive the upgraded Moderna or Pfizer vaccine as a single booster dose at least two months after the initial vaccination or the previous booster dose
.
5 years of age and older.
Members of the public can receive the upgraded Moderna or Pfizer vaccine as a single booster dose at least two months after the initial vaccination or the previous booster dose
.
On August 31 this year, the US Food and Drug Administration has approved the upgraded Moderna vaccine for people aged 18 and above, and the upgraded Pfizer vaccine for people
aged 12 and above.
The FDA said that the upgraded version of the vaccine is a bivalent vaccine that can work
better against the original strain of the new coronavirus and the new subtypes BA.
4 and BA.
5 spike proteins of the new coronavirus Omicron variant.
aged 12 and above.
The FDA said that the upgraded version of the vaccine is a bivalent vaccine that can work
better against the original strain of the new coronavirus and the new subtypes BA.
4 and BA.
5 spike proteins of the new coronavirus Omicron variant.
Peter Marks, director of the FDA's Center for Biologics Evaluation and Research, said the risk of exposure to the new coronavirus may increase
as children return to school and the public gradually resumes pre-pandemic activities.
Vaccination remains the most effective measure to
prevent the serious consequences of the coronavirus.
as children return to school and the public gradually resumes pre-pandemic activities.
Vaccination remains the most effective measure to
prevent the serious consequences of the coronavirus.
Max said that although children are usually less severe than adults after contracting the new crown, there is an "surge" of cases in which more and more children are infected with the new crown and hospitalized
.
Even if the initial symptoms of infection are mild, children may still be affected
by "long-term coronavirus symptoms".
.
Even if the initial symptoms of infection are mild, children may still be affected
by "long-term coronavirus symptoms".
![1-METHYL-4-[5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABORALAN-2-YL)PYRIDINE-2-YL]PIPERAZINE](https://file.echemi.com/fileManage/upload/goodpicture/20210822/m20210822160345712.jpg)
